Biogen Inc.(BIIB)NASDAQ
Stock Performance & Returns
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
BIIB | 33.17 B | 40.16x | 3.40% | 8.32% | $5.59 | 4.58% | 0.44 | - | $222.85 | $133.53 |
REGN | 85.31 B | 20.87x | 16.70% | 27.87% | $40.42 | 14.04% | 8.54 | 47.00% | $847.00 | $538.24 |
950200.KQ | 66.17 B | - | 13.30% | -2.62% | - | -10.39% | 0.57 | - | $4690.00 | $2380.00 |
RVMD | 45.20 B | -24.02x | - | - | $-8.78 | -79.09% | 0.46 | - | $224.31 | $37.88 |
ALNY | 35.39 B | 45.45x | 66.90% | 16.13% | $5.82 | 96.56% | 2.21 | - | $495.55 | $197.81 |
Peer Valuation & Performance Analysis
Peer group analysis for Biogen Inc. (BIIB) compared to its primary competitors (including REGN, 950200.KQ, RVMD) reveals distinct metrics. BIIB trades at a valuation premium compared to its competitors, with a P/E ratio of 40.2x versus the peer average of 14.1x (representing a 185% premium). This indicates that the market expects superior growth or commands a quality premium for BIIB. In terms of growth, BIIB's revenue growth of 3.4% lags behind the peer average of 32.3%, indicating potential market share losses or slower industry adoption. Additionally, its net margin of 8.3% is below the peer average of 13.8%, suggesting higher operational costs or lower pricing power relative to peers.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• BIIB ranks #2 in P/E ratio, #4 in revenue growth, and #3 in profit margins
• Average ranking: #3 - 📊 Solid financials relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-09-03 | $225.44 | $225.80 | $221.23 | $224.51 | 550,700 | -0.41% |
| 2026-09-02 | $218.20 | $225.59 | $216.97 | $222.67 | 1,268,200 | +2.05% |
| 2026-09-01 | $218.11 | $219.30 | $213.60 | $216.04 | 785,500 | -0.95% |
| 2026-08-31 | $216.47 | $218.89 | $213.58 | $216.65 | 831,000 | +0.08% |
| 2026-08-28 | $221.17 | $222.00 | $216.78 | $218.50 | 517,400 | -1.21% |
| 2026-08-27 | $219.39 | $222.11 | $217.53 | $221.50 | 497,300 | +0.96% |
| 2026-08-26 | $219.34 | $222.00 | $218.69 | $221.07 | 647,200 | +0.79% |
| 2026-08-25 | $218.93 | $222.85 | $218.00 | $220.77 | 495,400 | +0.84% |
| 2026-08-24 | $216.40 | $218.50 | $213.96 | $218.12 | 649,800 | +0.79% |
| 2026-08-21 | $217.76 | $219.12 | $215.00 | $216.78 | 722,300 | -0.45% |
| 2026-08-20 | $217.98 | $221.29 | $214.16 | $214.35 | 808,600 | -1.67% |
| 2026-08-19 | $215.33 | $222.15 | $215.08 | $221.56 | 886,800 | +2.89% |
| 2026-08-18 | $211.00 | $214.07 | $210.01 | $212.55 | 694,000 | +0.73% |
| 2026-08-17 | $208.36 | $210.49 | $207.62 | $209.15 | 617,100 | +0.38% |
| 2026-08-14 | $210.01 | $210.79 | $208.22 | $209.83 | 554,400 | -0.09% |
Explore More Analysis for BIIB
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.